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Abstract
Diffuse midline glioma (DMG), H3 K27M-mutant, is a new entity in the updated WHO classification grouping
together diffuse intrinsic pontine gliomas and infiltrating glial neoplasms of the midline harboring the same
canonical mutation at the Lysine 27 of the histones H3 tail.
Two hundred and fifteen patients younger than 18 years old with centrally-reviewed pediatric high-grade gliomas
(pHGG) were included in this study. Comprehensive transcriptomic (n = 140) and methylation (n = 80) profiling was
performed depending on the material available, in order to assess the biological uniqueness of this new entity
compared to other midline and hemispheric pHGG.
Tumor classification based on gene expression (GE) data highlighted the similarity of K27M DMG independently of
their location along the midline. T-distributed Stochastic Neighbor Embedding (tSNE) analysis of methylation profiling
confirms the discrimination of DMG from other well defined supratentorial tumor subgroups. Patients with diffuse
intrinsic pontine gliomas (DIPG) and thalamic DMG exhibited a similarly poor prognosis (11.1 and 10.8 months median
overall survival, respectively). Interestingly, H3.1-K27M and H3.3-K27M primary tumor samples could be distinguished
based both on their GE and DNA methylation profiles, suggesting that they might arise from a different precursor or
from a different epigenetic reorganization.
These differences in DNA methylation profiles were conserved in glioma stem-like cell culture models of DIPG
which mimicked their corresponding primary tumor. ChIP-seq profiling of H3K27me3 in these models indicate
that H3.3-K27M mutated DIPG stem cells exhibit higher levels of H3K27 trimethylation which are correlated
with fewer genes expressed by RNAseq. When considering the global distribution of the H3K27me3 mark, we
observed that intergenic regions were more trimethylated in the H3.3-K27M mutated cells compared to the
H3.1-K27M mutated ones.
H3 K27M-mutant DMG represent a homogenous group of neoplasms compared to other pediatric gliomas
that could be further separated based on the type of histone H3 variant mutated and their respective
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epigenetic landscapes. As these characteristics drive different phenotypes, these findings may have important
implication for the design of future trials in these specific types of neoplasms.
Keywords: Pediatric high-grade glioma, Diffuse midline glioma, H3 K27M-mutant, Diffuse intrinsic pontine glioma,
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Introduction
Diffuse intrinsic pontine glioma and malignant midline
gliomas have the worst prognosis of all types of malig-
nant tumors in children and adolescents [3, 4, 10]. The
nosological shift in the 2016 WHO classification now
based on both phenotype and genotype has redefined
the family tree of diffuse gliomas [17]. Glial tumors are
now grouped according to their driver mutation, e.g.
IDH1 mutation, and their astrocytic or oligodendroglial
phenotypes which are often associated with additional
specific genetic alterations such as ATRX mutations or
1p/19q co-deletion, respectively. The discovery of recur-
rent mutations in the histone H3 genes in pediatric
high-grade glioma has definitively separated these
gliomas from the ones seen in adults [21, 26]. While
G34R/V mutations in the H3F3A gene are exclusively
found in the hemispheres, K27M/I mutations in several
histone H3 variants genes are specific to midline tumors
[23]. The 2016 release of the WHO classification has
therefore created a new entity to describe these latter
tumors as diffuse midline glioma, H3K27M mutant, irre-
spective of their specific location along the midline.
In pediatric brain tumors, location has however long
been seen as a master driver of oncogenesis that could
reflect their different cells of origin [8, 9]. Whether the
oncogenic driver mutation is overriding location as a
crucial determinant of oncogenesis is therefore to be
examined since biologic identity of all these tumors
would call for a common therapeutic framework. There
is however no reported data showing at once a similar
biology and outcome of diffuse midline gliomas (DMG)
irrespective of their location in the presence of a histone
H3-K27M mutation.
Moreover, we have shown two distinct forms of diffuse
intrinsic pontine gliomas according to the type of his-
tone H3 gene mutated, H3F3A versus HIST1H3B, with
respect to differentiation markers, oncogenic programs,
response to therapy and evolution [1, 2]. These muta-
tions are mutually exclusive either because their effect is
redundant [16] leading to a global loss of H3K27me3
repressive mark, or because they cannot transform the
same cell, suggesting the idea of distinct cells of origin.
The purpose of this work was therefore to better
characterize a large series of pediatric midline high grade
gliomas from the (epi)genomic, transcriptomic and anatomic
point of view in order to identify the respective influences of
these parameters on their biology described by their gene ex-
pression, methylome, and clinical behaviour.
Moreover, we compared the H3-K27me3 landscape
between the two main subgroups of DIPG, H3.1-K27M
and H3.3-K27M, in patient deriving cellular models.
Materials & methods
Central pathology review
High-grade glioma cases were reviewed centrally to con-
firm the diagnosis according to the 2007 WHO classifica-
tion and its 2016 update as previously described [10, 20].
Specific immunostainings were performed to detect
nuclear expression of the trimethylation mark at position
K27 of the histone 3 tail (1:1000, polyclonal rabbit anti-
body, Diagenode, Belgium) as well as nuclear expression
of the K27M form of histone H3 (1:1000, polyclonal
rabbit antibody, Millipore, CA).
Derivation and culture of glioma stem-like cells (GSCs)
GSCs were derived from DIPG tumors at diagnosis as
previously described [19]. Briefly, tumor cells were
mechanically dissociated from biopsies within 24 h of
surgery, and further cultured as an adherent monolayer
in laminin-coated flask (Sigma) in neural stem cells
medium consisting of NeuroCult NS-A proliferation
medium (Stemcell technologies) supplemented with hep-
arin (2 μg/mL, Stemcell technologies), human-basic FGF
(20 ng/ml, Peprotech), human-EGF (20 ng/ml, Pepro-
tech), PDGF-AA (10 ng/ml, Peprotech), and PDGF-BB
(10 ng/ml, Perprotech). Medium was renewed every
other day, and passaging performed when cells reached
80% confluence using Accutase (Thermo).
Case selection for overall survival analysis and gene
expression profiling by microarray
Frozen tissue samples were obtained from 119 pediatric
patients with brain tumors of WHO grade III and IV (all
locations, below 18 years old). The samples were col-
lected at Necker Hospital (Paris, France). Complete
follow-up information was available for 82.5% of patients
(n = 99). Histone H3 gene mutational status was deter-
mined by Sanger sequencing for H3F3A, HIST1H3B/C
and HIST2H3C [2]. The distribution of samples in the
distinct genotype subgroups and location are detailed
in Table 1.
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Case and sample selections for methylation analysis
Eighty primary tumor samples were selected for methy-
lome analysis: 22 among the DIPG patient cohort col-
lected in Necker Hospital; 15 from the HERBY trial [10],
all the remaining samples were collected by the Heidel-
berg group. The distribution of samples in the distinct
genotype subgroups and their location are detailed in
Table 2.
Gene expression profiling was also conducted by either
microarray or RNA sequencing for 5 of these tumors.
Eight glioma stem-like cell (GSC) cultures derived from
patient biopsies at diagnosis and matching primary
tumors were analyzed similarly [19].
Methylation profiling
DNA was extracted from tumors and genome-wide
DNA methylation analysis was performed using either
the Illumina HumanMethylation450 BeadChip (450 k)
or EPIC arrays. DNA methylation analysis was per-
formed with custom approaches as previously described
[12, 23]. DNA methylation profiles from 50 K27M
pHGG were compared to defined supratentorial tumor
subgroups, i.e. G34R-H3.3 mutated (n = 10), MYCN
(n = 10) and PDGFRA/pedRTK1 (n = 10) subgroup tu-
mors. For t-SNE analysis (t-Distributed Stochastic
Neighbor Embedding, Rtsne package version 0.11),
428,230 uniquely mapping autosomal probes in com-
mon between the 450 k and EPIC arrays were used.
The input for the t-SNE calculation is 1-Pearson
correlation, weighted by variance. Clustering analyses were
performed using the beta values of the top 10,000 most
variably methylated probes by standard deviation. Methy-
lation probes in the heatmap representation were
reordered by unsupervised hierarchical clustering using
Pearson correlation distance and median linkage.
Microarray gene expression profiling
Gene expression analysis was conducted on an Agilent
platform as previously described [2] but using RUV4
correction of batch effects [7] implemented in the R
package ruv. GE data from DIPG were collected from
one of our previous study [2] and microarray analysis
was performed for 75 additional pHGG tumors located
outside the brainstem. PCA, k-means and t-SNE analysis
were performed using the same parameters as for
RNA-seq data on the probes associated with the highest
standard deviation. One hundred and twenty genes ac-
counting for 0.79% of the entire probeset were selected.
RNA-seq gene expression profiling
RNA-seq was performed on 21 primary tumor samples.
Libraries were prepared using the TruSeq stranded
mRNA sample preparation kit according to the supplier
recommendations and paired-end sequencing was
conducted on Illumina NextSeq500 to generate a mean
of 150 million reads of 75 base pairs by sample.
Trimmed reads were then mapped using tophat2
(v2.1.0) and bowtie2 (v2.2.5) first to the reference tran-
scriptome, then to the reference genome for the
remaining reads. Genes with a row sum of raw counts
over the studied samples equal to or below 10 were fil-
tered out to remove non-expressed genes. We handled
outliers as default using minReplicatesForReplace = 7 in
DESeq() function used to estimate size factors, disper-
sion and model coefficients. Distances between samples
were computed by using ‘1-Pearson correlation coeffi-
cient’ as the distance measure. PCA and t-SNE analysis
were performed on the 250 genes associated with the
highest variance to keep the same proportion of genes
selected with the microarray analysis. All samples were
projected on the two first principal components com-
puted with rlog transformation of the counts of the
120 genes with the highest standard deviation. Using
Table 1 Contingency table of samples used for microarray gene
expression profiling and overall survival analysis
Tumor
location
Histone H3 mutational status Total
number
of samples
H3.3-
G34R
H3.1-
K27M
H3.3-
K27M
H3.1 &
H3.3-WT
Cortex 6 0 0 35 41
Pons 0 13 26 6 45
Non-thalamic
midline
0 0 2 12 14
Thalamic
midline
0 0 12 7 19
One hundred and nineteen high-grade glioma samples were divided in four
groups according to their location either in the pontine (DIPG), cortical or
thalamic area of the brain as well as the non-thalamic midline, i.e. spinal cord,
cerebellum or peduncle tumors classified as ‘non-thalamic midlines’
Table 2 Contingency table of samples used for methylation profiling
Tumor location Histone H3 mutational status PDGFRA
subgroup
MYCN
subgroup
Total
number of
samples
H3.3-G34R H3.1-K27M H3.3-K27M H3.2-K27M
Cortex 10 0 0 0 10 10 30
Pons 0 12 19 1 0 0 32
Thalamic midline 0 1 17 0 0 0 18
Eighty high grade gliomas were analyzed by 450 k and EPIC Illumina bead arrays. Tumor location and histone H3 mutations or PDGFRA and MYCN molecular
subgroups were considered for sample stratification
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Rtsne package (v 0.11), we applied t-SNE on the same
data matrix with the Pearson correlation as a distance
and the following parameters: theta = 0, perplexity =
min(floor((ncol(rlog_VariableGenes)-1)/3), 30), check_-
duplicates = FALSE, pca = FALSE, max_iter = 10,000,
verbose = TRUE, is_distance = TRUE.
RNA-seq was also performed on 6 distinct GSC models
using TruSeq stranded total RNA sample preparation kit
according to the supplier recommendations (Illumina)
and then processed similarly as primary tumors.
Histone ChIP-sequencing and data processing
ChIP-seq of H3K27me3 epigenetic modification was per-
formed in 6 GSC models at Active Motif according to
proprietary methods. The 75-nt sequence reads were
generated on a Illumina NextSeq 500 platform, mapped
using BWA algorithm and peak calling was performed
using SICER1.1 algorithm [27] with cutoff FDR 1e-10
and gap parameter of 600 bp. False positive ChIP-seq
peaks were removed as defined within the ENCODE
blacklist [5]. Overlapping intervals between the different
samples were merged, and the average number of nor-
malized reads in the different samples were calculated
for these 16,977 genomic intervals defined as ‘bound re-
gions’. These bound regions were separated for further
analysis in overlapping or not overlapping gene loci
using Genecode annotation (gencode.v19.chr_patch_-
hapl_scaff_annotation.gtf ). PCA for all samples were
generated after scaling to unit variance using the PCA
function from the FactoMineR package (v1.41) and plot-
ted using Factoextra (v1.0.5).
Merging of the 3 biological replicates of H3.1- or H3.3-
K27M subgroups was performed using bigWigMerge tool
(UCSC kent utils, http://hgdownload.soe.ucsc.edu/admin/
exe/macOSX.x86_64/). Heatmaps of H3K27me3 ChIPseq
enrichment across genomic loci were calculated using
deepTools version 1.5.11. ComputeMatrix was used with
regions of either +/− 5 kb or +/− 10 kb around the center
of the genomic intervals for ‘bound regions’ or TSS for
differentially expressed genes, respectively. Heatmaps were
plotted with or without k-means (k = 5) and their average
profiles of ChIP-Seq enrichment in the same − 10/+ 10 kb
genomic intervals were also generated for each k-means
group. The bigWig files (all signal) were annotated with
chipSeeker package using UCSC hg19 known gene annota-
tion and visualizated by peakAnno and Vennpie.
Survival curve comparisons
The distribution of overall survival (OS) was calculated
according to the Kaplan-Meier method and all survival
function estimate comparisons were performed in
PRISM software using a log-rank test. OS was calculated
from the date of histo-radiological diagnosis until death
of patient from disease or last contact for patients who
were still alive.
Results
Histone H3 K27M midline pHGG and K27M DIPG display
similar gene expression profiles and survival but differ
significantly from other high-grade gliomas
We conducted microarray gene expression profiling of
the single center cohort from Necker Enfants Malades
hospital of 119 pHGG with histone H3 genotype previ-
ously determined either by Whole Genome Sequencing
[25] or targeted Sanger sequencing [2] (Table 1 and
Additional file 1: Table S1). In total, 131 distinct gene
expression microarrays were hybridized as 12 samples
were analyzed twice to control for potential batch ef-
fects. The 12 duplicated samples were located in close
proximity on PCA plot when projected on the 2 first
principal components, confirming the appropriate re-
moval of a batch effect in our dataset (data not shown).
Then, we selected a set of genes associated with the high-
est standard deviation for subsequent tumor classification
analysis (n = 120). Gene Ontology over-representation
analysis showed an enrichment of genes involved in brain
development (Bonferroni adjusted p-value 8.29e-09) and
morphogenesis (adjusted p-value 2.67e-07); many homeo-
box genes belong to this later set of genes reflecting prob-
ably the differences in tumor location.
Principal component analysis (PCA) was performed to
highlight the principal sources of variation among
pHGG tumors (Additional file 2: Table S2: weight in
principal components 1 and 2 associated to each gene).
The DIPG group appeared rather homogenous as all
samples clustered together in the PCA plot, separated
from the tumors originating from thalamic or cortical
areas of the brain which were more scattered (Fig. 1a).
Considering the mutational status of histone H3 genes,
the results clearly showed that H3-K27M tumors, which-
ever their pontine or thalamic location, could be sepa-
rated from the wild-type and G34R/V tumors on the
first principal component (Fig. 1b). Indeed, all H3-K27M
mutated thalamic and spinal tumors were close to DIPG
samples, whereas histone H3 wild-type thalamic tumors
are distributed on the right side of the plot among his-
tone H3 wild-type non-thalamic midline and cortical tu-
mors. Interestingly, 5 DIPG without any mutation in
H3F3A, HIST1H3B/C and HIST2H3A/C were located
within the K27M DIPG subgroup. These tumors all
showed H3K27-trimethylation loss by immunohisto-
chemistry (Additional file 3: Figure S1A). Unsupervised
K-means analysis was performed on the same dataset
(using k = 2 which showed the best BIC value) and led to a
similar conclusion as the k-mean group 1 corresponded to
H3-K27M and H3-wild type samples presenting
H3K27-trimethylation loss whereas k-mean group 2
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contained all other pHGG tumors (Additional file 3:
Figure S1B). Additionally, this GE dataset was analyzed in
parallel with another dimension reduction and
visualization technique for high-dimensional data, t-SNE,
as it was shown to be more robust than PCA with respect
to outliers. Moreover, t-SNE has also been frequently used
for pediatric brain tumor classification based on DNA
methylation profiles [23]. This analysis of GE profiles led
to similar observations, re-iterating the similarity of
H3-K27M thalamic midline and DIPG (Additional file 3:
Figure S1C-D). Histone H3-G34R/V samples were
tightly clustered together in particular in this analysis,
thus reflecting a strong similarity in their gene ex-
pression profiles.
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Fig. 1 Gene-expression based classification of high-grade gliomas and corresponding survival analyses. Principal component analysis of
microarray GE profiling of 119 high-grade gliomas. In total, 131 data points are represented as 11 samples were duplicated allowing to monitor
the batch effect correction. The genes associated with the highest standard deviation were selected (n = 120 genes) for the analysis and the
tumors were color-coded according to their location (a) or mutational histone H3 status (b). Four groups were defined in the upper left panel
corresponding to cortical (yellow), thalamic (black), pontine (pink) and non-thalamic midline (grey) glioma. In the right panel, the samples were
divided in 4 subgroups according to the mutational status of histone H3 genes: H3.3-G34R (blue), H3.3-K27M (light green), H3.1-K27M (dark
green) mutated tumors and tumors without any alteration of either H3F3A, HIST1H3B and HIST2H3A genes (grey). c Kaplan–Meier of the overall
survival of patients with a high-grade glioma stratified by their location. DIPG (green) and thalamic (black) tumors are associated with the shortest
overall survival (median of 11.1 months and 10.8 months respectively). The midline tumors (grey) which are located outside the thalamus show
the most favorable prognosis. The subgroup of cortical tumors (yellow) shows an intermediate phenotype (median survival 30.5 months). Log
rank test p-value < 0.0001. d Kaplan–Meier survival curves of patients with a midline HGG stratified by both tumor location and H3-K27 mutational
status. The overall survival is rather similar for all tumor subgroups (overall median survival about 10.8, 13.86, 10.02, 10.5 months for K27M DIPG, WT
DIPG, K27M midline, WT thalamus, respectively) except for the WT non-thalamic midline tumors presenting a much better prognosis. Log rank test
p-value < 0.0001
Castel et al. Acta Neuropathologica Communications           (2018) 6:117 Page 5 of 13
In agreement with these observations, a huge number of
differentially expressed genes were identified between
H3-K27M and H3-wild-type tumors as well as between
H3-K27M and H3-G34R tumors (adjusted p-value < 0.01)
in comparison with the other contrasts (Additional file 3:
Figure S1E and Additional file 4: Table S3). In contrast,
only 14 genes were significantly modulated between
H3-G34R and H3-WT tumors which were not discrimi-
nated by PC1 (Fig. 1b). Gene ontology analysis showed an
important enrichment of modulated genes associated with
neurogenesis (4.37e-12 – 1.41e-11) and neuron differenti-
ation (3e-07 - 4.87e-13) signaling pathways in both
contrasts (H3-K27M vs. H3-WT and H3-K27M vs.
H3-G34R) , as well as an upregulation of genes involved
in ion transmembrane transport (1.6e-04) and apoptotic
processes (5.9e-18) and an downregulation of genes linked
to cell cycle (8.3e-11) and gliogenesis (6.87e-10) in the
case of the comparison between H3-wild-type and
H3-K27M tumors. Also, geneset enrichment analysis
(GSEA) identified the ontology GO_oligodendrocyte_
differentiation (Enrichment Score 0.70) enriched in upreg-
ulated genes in H3-K27M tumors and GO_Cerebral_
cortex_neuron_differentiation (Enrichment Score − 0.79)
enriched in genes upregulated in H3-G34R. Some of these
biological processes were previously identified as signifi-
cantly enriched in differentially expressed genes when
comparing H3.1- and H3.3-K27M tumors [2].
We next conducted a survival analysis on this cohort
(n = 119) using only location information and then both
location and H3 mutation status for patient stratification
(Fig. 1c and d). DIPG and thalamic tumors were associ-
ated with similar poor prognosis, i.e. 11.1 and
10.8 months median OS, respectively. Non-thalamic
midline tumors exhibited the best prognosis (median OS
not reached), whereas tumors arising in the cortex pre-
sented an intermediate outcome with a median survival
around 30.5 months (p-value < 0.0001, Fig. 1c). Focusing
on Kaplan-Meier estimates for midline tumors, our data
clearly indicate that H3-WT non-thalamic midline have
a significantly higher overall survival, whereas the other
midline malignant gliomas (mostly thalamic), with or
without alteration of histone H3 genes, display equiva-
lent poor survival (p-value < 0.0001, Fig. 1d).
Methylation profiling separates HIST1H3B and H3F3A
K27M tumors
Previous studies have shown that genome-wide DNA
methylation data can provide a robust classification of
pediatric brain tumors into clinically meaningful epigenetic
subgroups mostly characterized by recurrent genetic alter-
ations [14, 15, 22]. Consequently, we compared the methy-
lation profiles of K27M-mutated diffuse midline gliomas
(including DIPG) to G34R-mutated tumors and well-
characterized supratentorial tumors without mutation in
histone H3 genes, i.e. MYCN and PDGFRA tumor sub-
groups (Fig. 2a, Table 2) [15]. Eighty primary tumor sam-
ples were used in this analysis and t-SNE visualization of
the DNA methylation data was conducted. We confirmed
that H3-G34R, PDGFRA and MYCN subgroups constitute
3 distinct homogenous entities, as they defined three dis-
tinct clusters. All H3-K27M samples were located on the
opposite side of the 2D representation, reflecting important
differences in the methylome compared to these three
well-defined pHGG subgroups. This observation was thus
concordant with our results on GE profiling by microarray.
In addition, the same methylation profiling splits
H3-K27M samples in two subgroups that corresponded
to either H3.1 or H3.3 mutated tumors. The obvious
separation of these tumors in an analysis containing
other very distinct biological entities clearly indicated
the significant difference between them. Also, the unique
H3.2-K27M sample appeared closer to H3.1-K27M than
H3.3-K27M samples (Fig. 2a).
The same classification by t-SNE was repeated for the
subset of H3-K27M mutated midline gliomas. First,
t-SNE analysis did not reveal a segregation of these
samples according to their location, as all DIPG and
thalamic midline were scattered in the 2D plot (Fig. 2b).
Conversely, when considering samples based on the
mutated histone H3 gene, the t-SNE analysis clearly
highlighted two non-overlapping subgroups correspond-
ing to H3.1/H3.2-K27M and H3.3-K27M classes (Fig. 2c).
This observation indicates that H3.3-K27M DIPG are
closer to other midline H3.3-K27M HGG than to
H3.1-K27M DIPG. The histone H3 variant affected by
the K27M substitution thus has a stronger correlation
with the modulation of DNA methylation profile than
the tumor location across the midline.
An additional analysis was performed on a subset of
21 primary DIPG tumors and 8 glioma stem-like cells
(GSCs) deriving from these same biopsies. The sample
classification by unsupervised hierarchical clustering
confirmed the previous result, with two main clusters
corresponding to H3.3-K27M and H3.1/2-K27M sam-
ples (Fig. 3a). Additionally, we observed that the major-
ity of the GSCs clustered with their corresponding
primary tumors indicating the close similarity of their
methylome profile. This consequently underlined that
GSC population remained very similar to their primary
counterpart with respect to DNA methylation, reflecting
the variation in DNA methylation observed between the
two subgroups of H3.1 and H3.3 mutated tumors.
RNA-seq profiling also discriminates HIST1H3B/C and
H3F3A K27M mutated gliomas
DNA methylation is a relatively stable component of the
epigenome involved in the establishment and mainten-
ance of distinct gene expression patterns. Consequently,
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we decided to evaluate if the different DNA methylation
profiles were associated with distinct transcriptome pro-
files. PCA analysis of GE measurements by microarrays
did not clearly discriminate H3.1 and H3.3 mutated
tumor samples (Fig. 1b). Indeed, even if H3.1-K27M
DIPG were closer to each other in the 2-dimensional
PCA plot, they are surrounded by H3.3-K27M samples.
However, as microarray data were generated in several
batches, we could not exclude that this could obscure
the dataset, despite the use of a batch correction
method. Therefore, we took advantage of a RNA-seq
study of 21 new H3-K27M DIPGs samples which
appeared more suitable as it provides an exhaustive
measurement of transcriptome in contrast to microarray
analysis. Grouping of tumors based on their RNA-seq
expression profiles in either t-SNE or PCA classifications
confirmed the discrimination of H3.1-K27M from
H3.3-K27M tumors observed in our DNA methylation
study (Fig. 3b and Additional file 5: Figure S2).
H3.1- and H3.3-K27M mutations are associated with
different genomic distribution of the H3K27me3
epigenetic mark
To complement the description of the epigenetic land-
scape of DIPGs, we decided to assess the direct epigen-
etic consequences of the K27M mutation in H3.1-K27M
and H3.3-K27M tumors, i.e. the loss and redistribution
of the trimethylation mark at position K27. We thus
took advantage of 6 GSC models of different genotypes
as an expandable source of material and interrogated the
genome-wide distribution of this mark with ChIP-seq.
We conducted a PCA analysis on all genomic regions
showing enrichment for this mark and could again sep-
arate the samples based on the type of mutated histone
(Fig. 3c). This implied that despite the similar bio-
chemical impact of both H3.1-K27M and H3.3-K27M
mutated histones on PRC2, interferences of the two
Fig. 2 Classification of high-grade gliomas based on genome-wide
DNA methylation profiles. a t-SNE analysis of the methylation profiles of
80 pediatric high-grade gliomas using the topmost differentially
methylated probes across the sample set (s.d. > 0.25). Midline tumors are
color-coded according to the histone H3 gene mutated: dark green for
H3.1-K27M (n = 13), purple for H3.2-K27M (n= 1) and light green for
H3.3-K27M tumors (n= 36). Others H3-WT high-grade glioma are also
presented: H3.3-G34R mutated tumors (n= 10, blue), PDGFRA (n= 10,
orange) and MYCN (n= 10, brown) amplified tumors. b-c Analysis of
methylation patterns of 50 pediatric H3-K27M midline tumors by t-SNE
indicates that H3.1-K27M and H3.3-K27M tumors are clearly distinct from
each other. Dimensionality reduction and visualization of methylome
data was performed by t-SNE after selection of the probes with the
greatest variance (n= 10,000; See Methods). Samples were color-coded
according to their location (b), the histone H3 gene mutated (c). t-SNE
show two main clusters corresponding to H3.1/H3.2-K27M and
H3.3-K27M subgrouping
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different mutated histones H3 on PRC2 is not similarly
distributed in the genome and this may induce meaning-
ful changes in the epigenetic landscapes of these DIPGs.
The average signal of all H3K27me3 peak regions
was equivalent in H3.1- and H3.3-K27M tumors
(Additional file 6: Figure S3A, top). We plotted the
ChIP-seq signal of the union of H3K27me3 peaks
identified from all the GSC samples and did not observed
a specificity of the genomic regions presenting a
H3K27me3 deposition between H3.1 and H3.3 K27M
subgroups but rather a difference in the level of the signal
enrichment (Additional file 6: Figure S3A, bottom). How-
ever, the genome distribution of H3K27me3 showed an
enrichment of peaks in distal intergenic regions in
H3.3-K27M GSC and in contrast in intronic and at a
lesser extent exonic regions in H3.1-K27M cells (Fig. 4a).
Subsequently, we divided the active genomic loci
presenting H3K27me3 deposition according to their lo-
cation. Overall, the global signal was significantly higher
in regions overlapping genes versus intergenic regions
(Additional file 6: Figure S3B-C). The heatmap displayed
that the majority of regions overlapping genes presented
a lower level of H3K27me3 in H3.1-K27M samples
(Additional file 6: Figure S3C). This observation was
concordant with a higher number of expressed genes in
H3.1, which are moreover associated with higher expres-
sion levels (Additional file 6: Figure S3D).
The clustering of genomic intervals by k-means
highlighted the existence of distinct subgroups of loci,
smaller gene clusters with a significantly higher level of
H3K27me3 in H3.1-mutated cells (C1, C2 and C3 for
genic and C1’ and C3’ for intergenic loci, Fig. 4b and c
respectively). Consequently, the vast majority of loci
were enriched in K27me3 in H3.3-mutated cells.
Thereafter, we focused on the differentially expressed
genes identified by RNA-seq between the 2 subgroups
(adj p-value< 0.01). The results showed that upregulated
genes in H3.1-K27M are associated with a lower average
signal of H3K27me3 and vice et versa for downregulated
genes (Fig. 5a). The ChIP-seq read coverage are shown
for two representative genes, OLIG2 and SLFN11, even
Fig. 3 Subclassification of DIPG based on RNA-seq, methylome and
H3K27me3 epigenetic profiles. a Heatmap and hierarchical clustering
of the Pearson correlation matrix of 19 DIPG and 8 matched GSC
cultures (H3.3-K27M and H3.1-K27M in light and dark green respectively)
across 3209 probes used for DNA methylation measurements. b t-SNE
analysis of RNA-seq data in DIPG. RNA sequencing of 21 DIPG samples was
performed and the genes associated with the highest standard deviation
(n=250) were selected to conduct t-SNE analysis. The tumors were color-
coded according to histone H3 mutated, i.e. H3.3-K27M in light green and
H3.1-K27M in dark green. c Principal component analysis of 3 H3.1- and 3
H3.3-K27M GSC models of DIPG based on H3K27me3 epigenetic mark
profiling (n= 16,977 genomic intervals)
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if distinct localization of H3K27me3 is observed between
both, located mainly upstream and downstream of tran-
scribed region for SLFN11 and overlapping gene body
for OLIG2 (Fig. 5b and c). However, gene expression
modulations between H3.1- and H3.3-mutated tumors
was not restricted to changes in H3K27me3 deposition
at the close vicinity of the gene body as shown for
HOXD8 which is upregulated and associated with an in-
creased H3K27me3 deposition in H3.1-K27M tumors
(Fig. 5d).
Discussion and conclusions
The recent update of the WHO classification aggregated
DIPG and infiltrating glial neoplasms of the midline pre-
senting a H3-K27M substitution as a new entity: diffuse
midline glioma (DMG) H3 K27M-mutant. But this im-
plied that the histone H3-K27M would be a stronger
driver of oncogenesis than location. We used a pHGG
cohort at diagnosis to evaluate the similarity of these
H3-K27M mutated tumors at both DNA methylation
and gene expression levels and compared them to other
pHGG tumor subgroups in order to support or question
the new update of the WHO classification [23].
Tumor classification based on microarray gene expres-
sion profiling revealed that K27M mutated tumors, ei-
ther thalamic or pontine, can be discriminated from all
others. Consequently, the molecular subtype appears to
influence more the gene expression profile than the
infratentorial vs. supratentorial location of the tumor in
the brain. Alternatively, location may not be considered
at the structural level (i.e. brainstem vs. thalamus) but
rather at the embryological level (midline vs. hemi-
spheres) thus unifying midline tumors. Accordingly, sur-
vival analyses highlighted a similarly poor prognosis for
DIPG and thalamic tumors, either mutated or not for
histone H3. The bad outcome of all midline gliomas
with K27M mutations was also observed by Karreman
et al. [13]. Taken together these data support the ration-
ale to define the same treatment paradigms for both
midline K27M tumors and DIPG.
The stratification based on DNA methylation profiling
of our pHGG population also supports the similarity
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between thalamic and pontine H3-K27M tumors. Our
results are concordant with previous reports concerning
the discrimination of G34R/V and K27M mutated tu-
mors depending on DNA methylation [18, 23]. More-
over, t-SNE analysis highlighted a clear distinction of
H3-K27M tumors from all other pHGG subtypes. In-
deed, G34 mutated tumors, PDGFRA and MYCN sub-
types represent three homogenous groups distinct from
K27M tumors.
The DIPG median survival was similar to the large
retrospective pHGG cohort recently analyzed by Mac-
Kay and collaborators [18]. However, midline and hemi-
spheric tumors were associated with longer median
survival in our cohort, 18 versus 13.5 months and 30.5
versus 18 months, respectively. Survival analyses also
pointed out a significantly better outcome of histone H3
wild-type non-thalamic midline tumors, which likely re-
flects that they may be less diffusely growing gliomas and
could therefore be more amenable to surgical resection, or
that they exhibit a behavior of low-grade gliomas.
Finally, in the gene expression analysis some diffuse
midline gliomas without any H3-K27M mutation are
grouped with the H3K27M tumors. Interestingly, they
all exhibit a loss of the H3K27me3 mark as well. Thus,
defining the entity by the H3K27M mutation only may
therefore be too restrictive. Further studies are needed
to sort this issue, especially since diffuse pontine and
thalamic malignant gliomas have a poor prognosis irre-
spective of the presence of an H3K27M mutation or not
as also recently shown in the HERBY trial (Mackay et al.,
Cancer Cell 2018).
Interestingly, our methylation profiling data showed a
subclassification of DMG, H3 K27M-mutant into two
subgroups according to the histone gene affected by the
K27M substitution, i.e. H3F3A or HIST1H3B/C. The sole
H3.2-K27M sample clustered together with H3.1-K27M
tumors, as expected given that they are both canonical
histone H3 with identical role in the cell [24]. Yet, the
similarity of H3.1 and H3.2 mutated tumors should be
confirmed with additional H3.2 mutated samples from
other cohorts, as only two were reported in the literature
[2, 18]. Histone H3.1 and H3.3-K27M tumors were also
discriminated by RNAseq transcriptome profiling, sup-
porting their intrinsic divergence. This could support
the recently reported superiority of RNAseq over expres-
sion microarrays for tumor classification purposes [28].
MacKay and coll. did not report this distinction between
H3.1 and H3.3 mutated tumors using DNA methylation
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profiling. This difference might result from a 10 times
smaller proportion of H3.1 mutated samples analyzed (8
out of 441 samples) hiding out the variability brought by
these tumors in their huge dataset. In addition, we used
a 7 times larger set of probes (10,000 instead of 1381)
that might have captured more variations in the overall
pHGG DNA methylation landscape.
It is assumed -and was recently demonstrated by
Hoadley et al., that DNA methylation can reflect the
epigenetic memory of cancer cell-of-origin [11]. Indeed,
DNA methylation is inherited through successive di-
vision and is shown to be not only tumor-type specific,
but can also reflect the cell type and differentiation state
of the transformed cells [6]. The clear separation by
DNA methylation profiling of H3.1-K27M from
H3.3-K27M tumors may support that these tumors
would arise from distinct cells of origin or at distinct
differentiation steps in the lineage. This strongly corro-
borates our previous results showing that DIPG can be
divided in two main H3.1-K27M and H3.3-K27M tumor
subgroups, associated with distinct histological and mo-
lecular phenotypes, age of onset and location along the
midline, H3.1-K27M mutation being almost exclusively
seen in the brainstem while H3.3-K27M mutation are
distributed everywhere along the midline [2]. Also, the
conservation of DNA methylation discrepancies in GSCs
confirm they are intrinsic characteristic of the tumor
cells as opposed to the peri-tumor stroma. Furthermore,
we demonstrate that despite the same global bio-
chemical consequence of the H3K27M driver mutation,
significant differences exist in the H3K27me3 landscape
relying on the type of histone H3 variant affected (i.e.
H3.1 or H3.3) as shown by PCA.
As a whole, the distribution of the H3K27me3 marks
along the genome is different, both at the quantitative
and qualitative levels. Average level of trimethylation at
K27 is similar in both subtypes since only a small
number of loci are highly enriched in H3K27me3 in
H3.1 K27M mutated tumors, whereas the majority of
the regions presenting this epigenetic mark are as-
sociated with a higher signal in H3.3-K27M. These
H3K27me3 variations among the two subgroups are as-
sociated with the modulations of gene expression, many
more genes being repressed in H3.3-K27M tumors.
Qualitatively, K-means clustering of the distribution of
this mark identified 5 clusters of genic regions and 5
clusters of intergenic regions differentially trimethylated
at position K27 in the two subgroups of DIPG. We show
that among differentially expressed genes, levels of
H3K27me3 are anti-correlated with gene expression in
general. However, gene expression could not be strictly
explained by the levels of H3K27me3 in all cases leaving
the possibility of additional levels of regulation for gene
expression in DIPG.
Overall, we provide molecular and clinical evidence in
favor of the unification of all midline K27M mutated tu-
mors that was proposed in the 2016 WHO CNS classifica-
tion based on their common driver mutation. As such,
these gliomas need to be considered as a unique entity in
future clinical trials. Further analyses on the biology of
H3.3 and H3.1 mutated diffuse gliomas are required to ex-
plain the distinction we have reported so far; this could
allow testing specific precision medicine approaches in
these two subgroups of diffuse midline gliomas.
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